Viva Biotech Holdings
Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2008, the company has established itself as a prominent provider of drug discovery services, specialising in structure-based drug design and high-throughput screening. Viva Biotech's unique offerings include its proprietary technology platforms that enhance the efficiency of drug development processes, setting it apart in a competitive market. With a strong focus on innovation, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and a robust portfolio of successful projects. Recognised for its expertise and commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to solidify its position as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viva Biotech Holdings's score of 20 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viva Biotech Holdings's reported carbon emissions
In 2023, Viva Biotech Holdings reported total carbon emissions of approximately 46,731,280 kg CO2e, comprising about 1,466,050 kg CO2e from Scope 1 and about 45,285,230 kg CO2e from Scope 2 emissions. This reflects a slight decrease from 2022, where emissions were approximately 46,779,490 kg CO2e. In 2021, the company recorded total emissions of about 37,456,150 kg CO2e, with Scope 1 emissions at approximately 958,110 kg CO2e and Scope 2 emissions at about 36,499,030 kg CO2e. The trend indicates a significant increase in emissions from 2021 to 2022, but a stabilisation in 2023. Viva Biotech has not disclosed any specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for Viva Biotech to establish clear goals to mitigate its carbon footprint and align with global climate standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 152,010 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 27,929,350 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viva Biotech Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
